Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2369
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials ; volume:23 ; number:1 ; day:23 ; month:6 ; year:2022 ; pages:1-10 ; date:12.2022
BMC nephrology ; 23, Heft 1 (23.6.2022), 1-10, 12.2022
- Urheber
-
Sapankaew, Tunlanut
Thadanipon, Kunlawat
Ruenroengbun, Narisa
Chaiyakittisopon, Kamolpat
Ingsathit, Atiporn
Numthavaj, Pawin
Chaiyakunapruk, Nathorn
McKay, Gareth
Attia, John
Thakkinstian, Ammarin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12882-022-02850-3
- URN
-
urn:nbn:de:101:1-2022081600032287538173
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sapankaew, Tunlanut
- Thadanipon, Kunlawat
- Ruenroengbun, Narisa
- Chaiyakittisopon, Kamolpat
- Ingsathit, Atiporn
- Numthavaj, Pawin
- Chaiyakunapruk, Nathorn
- McKay, Gareth
- Attia, John
- Thakkinstian, Ammarin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Factors associated with initiation and persistence of urate-lowering therapy
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Selective amyloid-β lowering agents
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Factors associated with initiation and persistence of urate-lowering therapy
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Selective amyloid-β lowering agents
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Factors associated with initiation and persistence of urate-lowering therapy
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Selective amyloid-β lowering agents
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis